Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 287

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 287
---
 event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. In addition, the Company will issue the underwriters 200,000 ordinary shares (230,000 if the over -allotmentoption is exercised in full). F-14 DRUGS MADE IN AMERICA ACQUISITION CORP.
NOTES TO FINANCIAL STATEMENTS
MAY 23, 2024 (INCEPTION) THROUGH SEPTEMBER 30, 2024 NOTE 7 — SHAREHOLDERS’ DEFICIT Preference Shares— The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per share with such designations, voting and other rights and preferences as may be determined from time to time by the Company’s board of directors. As of September30, 2024 and June 30, 2024, there were no preference shares issued or outstanding. Ordinary Shares— The Company is authorized to issue 220,000,000 ordinary shares with a par value of $0.0001 per share. Holders of ordinary shares are entitled to one vote for each share. As of September30, 2024 and June 30, 2024, there were 9,857,143 ordinary shares issued and outstanding, of which an aggregate of up to 1,285,714 ordinary shares are subject to surrender and forfeiture to the extent that the underwriters’ over -allotmentoption is not exercised in full or in part so that the number of Founder Shares will equal 30% of the Company’s issued and outstanding ordinary shares after the Proposed Public Offering (assuming Sponsor does not purchase any Public Shares in the Proposed Public Offering). Rights— Except in cases where the Company is not the surviving company in a business combination, each holder of a right will automatically receive one -eighth(1/8) of one ordinary share upon consummation of the initial Business Combination. The Company will not issue fractional shares in connection with an exchange of rights. Fractional shares will either be rounded down to the nearest whole share or otherwise addressed in accordance with the applicable provisions of Cayman law. In the event the Company is not the surviving company upon completion of the initial business combination, each holder of a right will be required to affirmatively convert his, her or its rights in order to receive the one -eighth(1/8) of one ordinary share underlying each right upon consummation of the Business Combination. If the